Joshua Sabari, MD

home / authors / joshua-sabari-md

Articles

ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape

Joshua Sabari, MD;Kennedy Ferruggia, Assistant Editor

Published: June 3rd 2025 | Updated: June 11th 2025

Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments.

raw vegetables with blood glucose meter, syringe, lancet and stethoscope on desk, diabetes healthy diet concept - Image credit: neirfy | stock.adobe.com

Published: June 12th 2025 | Updated: June 16th 2025

Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential Biomarkers

Published: June 10th 2025 | Updated: June 12th 2025

Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting Members

Published: June 2nd 2025 | Updated: June 11th 2025

NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular Care

Published: June 3rd 2025 | Updated: June 11th 2025

ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape

Published: May 30th 2025 | Updated: June 5th 2025

Emerging Data: Impacts of ROCKstar and AGAVE-201

Mother holding baby's foot with measles spots | Image Credit: © rostock-studio - stock.adobe.com

Published: April 18th 2025 | Updated: April 21st 2025

Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

Joshua Sabari, MD

Articles

Latest Updated Articles